Lonza

#CDMO #Lonza #Manufacturing #Merck #Mergers and acquisitions

Lonza signs agreement to acquire US CDMO network from Merck

Lonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck (Darmstadt, Germany) at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs. The acquisition expands Lonza’s US CDMO manufacturing footprint from four to nine sites and complements its global network… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Lonza

Lonza and InduPro to collaborate on next-gen ADC therapies 

Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies.  Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology… Read More

#Business & Investment #Cancer Research #News

Influenza virus
#Collaboration #Ethris #Lonza #mRNA #mRNA-based vaccines #Respiratory

Partners develop non-invasive mRNA vaccines

Ethris and Lonza have announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates.  The vaccines are designed for mucosal delivery and offer a promising approach to combat respiratory diseases.  Room-temperature stability aims to address significant supply chain challenges associated with some… Read More

#News